Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


NL - FR - EN

Immunoglobulins

MULTIGAM 5% 10 g (200 ml) - 5 g (100 ml) - 2.5 g (50 ml) - 1 g (20 ml)
Therapeutic indications:
- substitution therapy
         1. primary immunodeficiency syndromes 
         2. secondary hypogammaglobulinemia in patients with chronic lymphatic leukaemia (CLL) and  
             multiple myeloma with recurring bacterial infections
         3. children with congenital AIDS who regularly suffer from bacterial infections
- immunomodulatory effect
         1. Idiopathic Thrombocytopenic Purpura (ITP)
         2. allogeneic bone marrow transplant
         3. Kawasaki Syndrome
- acute inflammatory polyneuropathy (Guillain-Barré Syndrome)
- Multifocal Motoric Neuropathy (MMN)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 

 

NEW!!!

MULTIGAM 10%

Therapeutic indications:

- substitution therapy

  1. primary immunodeficiency syndromes with impaired antibody production
  2. hypogammaglobulinemia and recurrent bacterial infections in patients with chronic lymphocytic leukemia, in whom prophylactic antibiotics have failed
  3. hypogammaglobulinemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisations
  4. hypogammaglobulinemia in patients after allogenic haematopoietic stem cell transplantation (HSCT)
  5. congenital AIDS with recurrent bacterial infections

- immunomodulatory effect

  1. Idiopathic Thrombocytopenic Purpura (ITP) in patients at high risk of bleeding or prior to surgery to correct the platelet count
  2. Guillain-Barré syndrome
  3. Kawasaki disease

NANOGAM® 5% 
Therapeutic indications:
- Substitution therapy in adults, and children and adolescents (0-18 year) with:
          1. primary immunodeficiency syndromes with reduced production of antibodies
          2. hypogammaglobulinemia and recurrent bacterial infections in patients with chronic lymphocytic
              leukaemia in whom prophylactic antibiotics have failed
          3. hypogammaglobulinemia and recurrent bacterial infections in patients with multiple myeloma in the
              plateau stage, and who do not respond to vaccination against pneumococci
          4. hypogammaglobulinemia in patients after allogenic hematopoietic stem cell transplantation (HSCT)
          5. congenital aids with recurrent bacterial infections
- Immunomodulation in adults, and children and adolescents (0-18 years) with:
          1. idiopathic thrombocytopenic purpura (ITP) in patients with an increased bleeding risk or to correct the
              amount of platelets prior to surgical interventions
          2. Guillain Barré syndrome.
          3. Kawasaki disease.

Ivegam-CMV 5 g (vial 50 ml) - 1 g (ampoule 10 ml)
Therapeutic indications:
- prevention of cytomegalovirus (CMV) infection in immunodeficient patients and in patients experiencing
  immunosuppression, particularly following an organ transplant
- adjuvant treatment of a pre-existing cytomegalovirus (CMV) infection in patients experiencing reduced
  immunological defense, including premature babies, newborns, drug-induced immunosuppression or another
  form of immunodeficiency.

Hepacaf 5000 I.U. (100 ml)

Therapeutic indications:
- prevention of hepatitis B re-infection following liver transplant in HBsAg-positif patients (complementary
  therapy to liver transplant)